Asset Details
Do you wish to reserve the book?
Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11+ or ‐A33+ allele
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11+ or ‐A33+ allele
Do you wish to request the book?
Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11+ or ‐A33+ allele
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11+ or ‐A33+ allele
2017
Overview
The HLA‐A11 or ‐A33 allele is found in approximately 18% or 10% of the Asian population, respectively, but each of which is a minor allele worldwide, and therefore no clinical trials were previously conducted. To develop a therapeutic peptide vaccine for each of them, we investigated immunological responses of advanced cancer patients with the HLA‐A11+/A11+ (n = 18) or ‐A33+/A33+ (n = 13) allele to personalized peptide vaccine (PPV) regimens. The primary sites of HLA‐A11+/A11+ or ‐A33+/A33+ patients were the colon (n = 4 or 2), stomach (2 or 3), breast (3 or 2), lung and pancreas (2 or 2), and so on. For PPV, a maximum of four peptides were selected from nine different peptides capable of binding to HLA‐A11 and ‐A33 molecules based on the pre‐existing peptide‐specific IgG responses. There were no severe adverse events related to PPV. At the end of the first cycle, peptide‐specific CTL responses were augmented in 4/12 or 2/9 of HLA‐A11+/A11+ or ‐A33+/A33+ patients, while peptide‐specific IgG responses were augmented in 6/14 or 4/10 patients, respectively. Clinical responses consisted of four stable diseases and 14 progressive diseases in HLA‐A11+/A11+patients, versus seven and six in ‐A33+/A33+patients, respectively. Further clinical study of PPV could be recommended because of the safety and positive immunological responses. IgG boosting were observed in HLA‐A11+/A11+ patients and HLA‐A33+/A33+ patients after personalized peptide vaccine(PPV). The patients with higher rate of changes of peptide‐specific IgG titers after 2nd cycle of vaccination showed longer prognosis than those with lower rate.
Publisher
John Wiley and Sons Inc
Subject
/ Aged
/ Alleles
/ Cancer Vaccines - administration & dosage
/ Cancer Vaccines - adverse effects
/ Cancer Vaccines - immunology
/ Epitopes, T-Lymphocyte - immunology
/ Epitopes, T-Lymphocyte - metabolism
/ HLA‐A11
/ HLA‐A33
/ Humans
/ IgG
/ Immunoglobulin G - immunology
/ Interferon-gamma - immunology
/ Interferon-gamma - metabolism
/ Original
/ T-Lymphocytes, Cytotoxic - immunology
/ T-Lymphocytes, Cytotoxic - metabolism
/ Vaccination - adverse effects
/ Vaccines, Subunit - administration & dosage
/ Vaccines, Subunit - adverse effects
